SBTX Silverback Therapeutics

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer will participate in presentations at the Cantor Global Healthcare Conference and the Stifel Immunology and Inflammation Summit in September.

Details outlined below.

Cantor Global Healthcare Conference

Presentation (Fireside Chat): Wednesday, September 3, 2025

Time: 3:55 p.m. ET

Location: New York

A live webcast of the presentation will be available .

Stifel Immunology and Inflammation Summit

Presentation: Monday, September 15, 2025

Time: 12:00 p.m. ET

Location: Virtual

A live webcast of the presentation will be available .

To access the live and archived webcasts for the investor conferences, please visit the Events & Presentations page in the “Investors & Media” section of the Company’s website. A replay of each of the webcasts will be available for 30 days following the event.

About ARS Pharmaceuticals, Inc.

ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit .

Investor Contact:

Justin Chakma, ARS Pharma

Media Contact:

Christy Curran, Sam Brown Inc.



615.414.8668



EN
28/08/2025

Underlying

SBTXSilverback Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Silverback Therapeutics

 PRESS RELEASE
Free
SBTX Silverback Ther...

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer will participate in presentations at the Cantor Global Healthcare Conference and the Stifel Immunology and Inflammation Summit in September. Details outl...

10h / 7m 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and ...

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray) $15.7 million in revenue, including $12.8 million in neffy U.S. net product revenue in second quarter of 2025 Growth for neffy in the U.S. driven by increased payor access with additional near-term growth anticipated from national direct-to-consumer (DTC) campaign and pediatric co-promote partnership 93% commercial coverage achieved with streamlined prior authorization process with approval rates at the pharmacy benefit manager (PBM) comparable to overa...

August 13, 2025 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

ARS Pharmaceuticals Announces Conference Call and Webcast for its Seco...

ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Wednesday, August 13, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its second quarter 2025 financial results and business highlights. Dial-in information fo...

August 4, 2025 1 EN
 PRESS RELEASE
Free
SBTX Silverback Ther...

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First a...

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to market EURneffy in the U.K., expects availability in late Q3 2025 U.K. is the largest market outside the U.S. for adrenaline (epinephrine) auto-injector sales SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a ...

July 18, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.95
WHR WHIRLPOOL CORPO...
OXY Occidental Petr... ... (+31)

Vital Signs: Actionable charts

n this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

WHR WHIRLPOOL CORPORATION
OXY OCCIDENTAL PETROLEUM CORPORATION
VSAT VIASAT INC.
RDWR RADWARE LTD.
MRCY MERCURY SYSTEMS INC.
GTE GRAN TIERRA ENERGY
DAR DARLING INGREDIENTS INC.
AVAV AEROVIRONMENT INC.
EFR ENERGY FUELS
NEM NEMETSCHEK SE
FSLR FIRST SOLAR INC.
SJT SAN JUAN BASIN ROYALTY TRUST
LEU CENTRUS ENERGY CORPORATION
ISSC INNOVATIVE SOLUTIONS & SUPPORT INC.
SDRL SEADRILL LTD.
NEON NEONODE INC.
LHX L3HARRIS TECHNOLOGIES INC
JAN JANONE INC
MP MP MATERIALS CORP (A)
RTX RAYTHEON TECHNOLOGIES CORPORATION
APA APA CORPORATION
SHLS SHOALS TECHNOLOGIES GROUP
OVV OVINTIV INC
SBTX SILVERBACK THERAPEUTICS
CIVI CIVITAS RESOURCES INC
ASTS AST SPACEMOBILE INC
CHRD CHORD ENERGY CORPORATION
METC RAMACO RESOURCES INC.
UMAC UNUSUAL MACHS INC NEV
VG VENTURE GLOBAL INC.
OWLT OWLET INC
06/16/25 June 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch